PMV Pharmaceuticals, Inc. (PMVP)

Over the past six months, PMV Pharmaceuticals experienced a board chair transition with Laurie Stelzer succeeding Rich Heyman. The company reported its Q4 2025, Q3 2025 and Q2 2025 earnings. Evercore ISI lowered the company's price target to $4 from $16. The New England Journal of Medicine published first-in-human rezatapopt data. As of May 5, 2026, the share price was $1.38, representing an increase of 58.62% compared to May 6, 2025. The company participated in healthcare conferences and an Investor Webinar.

PMV Pharmaceuticals, as a clinical-stage company, does not experience traditional demand seasonality for products and services. Its revenue and operational focus are on research and development, and clinical trials. Stock price can be influenced by events such as presentations at major medical conferences or anticipated regulatory milestones.

PMV Pharmaceuticals, Inc. is a precision oncology company focused on developing small molecule, tumor-agnostic therapies targeting p53 mutations. Their lead product candidate, rezatapopt (PC14586), is in Phase 2 clinical trials and has received Fast Track designation from the FDA. The company anticipates submitting an NDA for rezatapopt in platinum-resistant/refractory ovarian cancer patients with a TP53 Y220C mutation in the first quarter of 2027.

PMV Pharmaceuticals, Inc. is headquartered in Princeton, New Jersey, United States, and primarily focuses on the discovery and development of therapies targeting p53 mutations within the United States.

PMV Pharmaceuticals' brand reputation is shaped by its progress in precision oncology and the development of rezatapopt. The publication of clinical data in the New England Journal of Medicine and the FDA's Fast Track designation have positively impacted its reputation. The board chair transition in April 2026 did not negatively impact the company's reputation.

PMV Pharmaceuticals has significant institutional ownership, with 67 institutional owners holding approximately 90.20% of the stock. Individual insiders hold about 7.57%, and the general public owns 33.4% of the shares. Major institutional owners include BML Capital Management, LLC, Orbimed Advisors Llc, Tang Capital Management Llc, ArrowMark Colorado Holdings LLC, and Sio Capital Management, LLC. Insider selling has been observed by OrbiMed Advisors LLC and individual insiders.